［1］ POSTOW MA,CALLAHAN MK,WOLCHOK JD.Immune checkpoint blockade in cancer therapy［J］.J Clin Oncol,2015,33(17):1974-1982.
［2］ KATO S,GOODMAN A,WALAVALKAR V,et al.Hyperprogressors after immunotherapy:Analysis of genomic alterations associated with accelerated growth rate［J］.Clin Cancer Res,2017,23(15):4242-4250.
［3］ LE DT,URAM JN,WANG H,et al.PD-1 blockade in tumors with mismatch-repair deficiency［J］.N Engl J Med,2015,372(26):2509-2520.
［4］ LE DT,DURHAM JN,SMITH KN,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade［J］.Science,2017,357(6349):409-413.
［5］ YARCHOAN M,HOPKINS A,JAFFEE EM.Tumor mutational burden and response rate to PD-1 inhibition［J］.N Engl J Med,2017,377(25):2500-2501.
［6］ GOODMAN AM,KATO S,BAZHENOVA L,et al.Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers［J］.Mol Cancer Ther,2017,16(11):2598-2608.
［7］ HARATANI K,HAYASHI H,TANAKA T,et al.Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment［J］.Ann Oncol,2017,28(7):1532-1539.
［8］ TOPALIAN SL,HODI FS,BRAHMER JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer［J］.N Engl J Med,2012,366(26):2443-2454.
［9］ GARON EB,RIZVI NA,HUI R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.N Engl J Med,2015,372(21):2018-2028.
［10］ READY N,HELLMANN MD,AWAD MM,et al.First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer(CheckMate 568):Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers［J］.J Clin Oncol，2019，37(12):992-1000.
［11］ BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer［J］.N Engl J Med,2015,373(2):123-135.
［12］ KILLOCK D.Lung cancer:Frontline nivolumab-CheckMate026 ends in stalemate［J］.Nat Rev Clin Oncol,2017,14(8):458-459.
［13］ CHEN J,JIANG CC,JIN L,et al.Regulation of PD-L1:A novel role of pro-survival signalling in cancer［J］.Ann Oncol,2016,27(3):409-416.
［14］ WITTE HM,GEBAUER N,LAPPOHN D,et al.Prognostic impact of PD-L1 expression in m-alignant salivary gland tumors as assessed by established scoring criteria:Tumor prop-ortion score(TPS),combined positivity score(CPS),and immune cell(IC)infiltrate［J］.Cancers(Basel),2020,12(4):873.
［15］ BATEMAN AC.DNA mismatch repair proteins:Scientific update and practical guide［J］.J Clin Pathol,2021,74(4):264-268.
［16］ DIAZ LA JR,LE DT.PD-1 blockade in tumors with mismatch-repair deficiency［J］.N Engl J Med,2015,372(20):1979.
［17］ MARABELLE A,LE DT,ASCIERTO PA,et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:Results from the phase II KEYNOTE-158 study［J］.J Clin Oncol,2020,38(1):1-10.
［18］ REMON J,BESSE B,SORIA JC.Successes and failures:What did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer［J］.BMC Med,2017,15(1):55.
［19］ SAMSTEIN RM,LEE CH,SHOUSHTARI AN,et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types［J］.Nat Genet,2019,51(2):202-206.
［20］ HU H,SHE L,LIAO M,et al.Cost-effectiveness analysis of nivolumab plus ipilimumab vs.chemotherapy as first-line therapy in advanced non-small cell lung cancer［J］.Front Oncol,2020,10:1649.
［21］ ZHANG Y,CHEN L.Classification of advanced human cancers based on tumor immunity in the microenvironment(TIME) for cancer immunotherapy［J］.JAMA Onnco,2012,(11):1403-1404.
［22］ 姜玉勃,刘昱辰,黄勇,等.PD-1/PD-L1免疫检查点抑制剂抗肿瘤治疗现状及其疗效预测标志物的研究进展［J］.癌症进展,2018,16(11):1319-1327.
JIANG YB,LIU YC,HUANG Y,et al.Current status of anti-tumor therapy with PD-1/PD-L1 immune checkpoint inhibitors and progress in their predictive markers for efficacy［J］.Oncology Progress,2018,16(11):1319-1327.
［23］ HAMID O,SCHMIDT H,NISSAN A,et al.A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma［J］.J Transl Med,2011,9:204.
［24］ GIDE TN,QUEK C,MENZIES AM,et al.Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy［J］.Cancer Cell,2019,35(2):238-255.e6.
［25］ TANIZAKI J,HARATANI K,HAYASHI H,et al.Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab［J］.J Thorac Oncol,2018,13(1):97-105.
［26］ PARIKH K,KUMAR A,AHMED J,et al.Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer［J］.Cancer Immunol Immunother,2018,67(9):1365-1370.
［27］ SANCHEZ GASTALDO A,MUNOZ FUENTES MA,MOLINA PINELO S,et al.Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab［J］.Transl Lung Cancer Res,2021,10(6):2509-2522.
［28］ OWNBY HE,ROI LD,ISENBERG RR,et al.Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer［J］.Cancer,1983,52(1):126-130.
［29］ SACDALAN DB,LUCERO JA,SACDALAN DL.Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors:A review and meta analysis［J］.Onco Targets Ther,2018,11:955-965.
［30］ JIANG T,QIAO M,ZHAO C,et al.Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy:A meta-analysis［J］.Cancer Immunol Immunother,2018,67(5):713-727.
［31］ OYA Y,YOSHIDA T,KURODA H,et al.Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer［J］.Oncotarget,2017,8(61):103117-103128.
［32］ KAMPHORST AO,PILLAI RN,YANG S,et al.Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targetedtherapy in lung cancer patients［J］.Proc Natl Acad Sci USA,2017,114(19):4993-4998.
［33］ PALLES C,CAZIERJ B,HOWARTH KM,et al.Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas［J］.Nature Genetics,2013,45(2):136-144.
［34］ CHURCH DN,BRIGGS SE,PALLES C,et al.DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer［J］.Hum Mol Genet,2013,22(14):2820-2828.
［35］ ANDRIANOVA MA,BAZYKIN GA,NIKOLAEV SI,et al.Human mismatch repair system balances mutation rates between strands by removing more mismatches from the lagging strand［J］.Genome Res,2017,27(8):1336-1343.
［36］ 黄润杰,关文龙,王峰.消化道肿瘤免疫检查点抑制剂疗效预测分子标志物研究进展［J］.中国癌症防治杂志，2022，14（02）：130-138.
HUANG RJ,GUAN WL,WANG F.Progress in molecular markers predicting the efficacy of immune checkpoint inhibitors in digestive tract tumors［J］.Chin J of Onco Prev and Treat，2022，14（02）：130-138.
［37］ STASENKO M,TUNNAGE I,ASHLEY CW,et al.Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer［J］.Gynecol Oncol,2020,156(1):194-202.
［38］ CHEN J,LOU H.Complete response to pembrolizumab in advanced colon cancer harboring somatic pole f367s mutation with microsatellite stability status:A case study［J］.Onco Targets Ther,2021,14:1791-1796.
［39］ ZHONG X,ZHANG H,ZHU Y,et al.Circulating tumor cells in cancer patients:Developments and clinical applications for immunotherapy［J］.Mol Cancer,2020,19(1):15.
［40］ GUIBERT N,DELAUNAY M,LUSQUE A,et al.PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab［J］.Lung Cancer,2018,120:108-112.
［41］ WANG Y,KIM TH,FOULADDEL S,et al.PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer［J］.SciRep,2019,9(1):566.
［42］ 陈鸿志,周永慧,李燕,等.免疫检查点抑制剂联合放化疗治疗非小细胞肺癌的疗效预测标志物研究进展［J］.临床肺科杂志,2022,27(1):5.
CHEN HZ,ZHOU YH,LI Y,et al.Progress in predictive markers of efficacy of immune checkpoint inhibitors combined with chemoradiotherapy in the treatment of non-small cell lung cancer［J］.Journal of Clinical Pulmonary Medicine,2022,27(1):5.
［43］ OBATA Y,FURUSAWA Y,ENDO TA,et al.The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells［J］.Nat Immunol,2014,15(6):571-579.
［44］ JIN Y,DONG H,XIA L,et al.The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC［J］.J Thorac Oncol,2019,14(8):1378-1389.
［45］ LI L,YE J.Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors:A Chinese population-based study［J］.Medicine(Baltimore),2020,99(37):e21788.